INTS Intensity Therapeutics, Inc.
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
INTS
—
—
What changed
Recent filings, trades and moves- Nov 5 8-K: Earnings results
- Nov 5 Quarterly report (10-Q) filed
Key stats
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 7
- List Date
- 2023-06-30
- CIK
- 0001567264
- Last Earnings
- Aug 11
- Headquarters
- Shelton, CT
- Homepage
- https://www.intensitytherapeutics.com
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotox…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|
| Jan | -- | -43.25% | 26.29% | -10.17% | -9.04% |
| Feb | -- | -25.85% | 8.84% | -16.44% | -11.15% |
| Mar | -- | 30.33% | -15.45% | -22.43% | -2.52% |
| Apr | -- | -21.84% | -71.45% | -8.43% | -33.91% |
| May | -- | 29.09% | -14.99% | -15.41% | -0.44% |
| Jun | 0.00% | 0.00% | -48.05% | -6.61% | -13.66% |
| Jul | -7.74% | -1.63% | -10.12% | -0.36% | -4.96% |
| Aug | -4.06% | -10.12% | 17.99% | -1.17% | 0.66% |
| Sep | -29.73% | -10.54% | -11.75% | -17.20% | -17.30% |
| Oct | -31.75% | -16.19% | 183.24% | 5.92% | 35.30% |
| Nov | -19.66% | -11.77% | -35.60% | -8.16%* | -18.80% |
| Dec | 172.06% | -38.81% | 7.89% | -- | 47.05% |
| Total | -7.21% | -80.20% | -73.01% | -66.59% | -56.75% |
* Only 4 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $3.30
SMA 50: $3.61
SMA 200: $5.02
Current: $3.15
EMA 12: $3.26
EMA 26: $3.38
MACD: -0.1158 | Signal: 0.0017
BEARISH
ADX (14): 12.42
RANGE
+DI: 13.16
−DI: 23.23
Momentum Oscillators
RSI (14): 42.08
NEUTRAL
Stoch %K: 36.52
Stoch %D: 50.61
Williams %R: -54.89
Volume & Volatility
BB Upper: $3.57
BB Lower: $3.02
NEUTRAL
OBV: 47,515,177
Vol SMA 20: 20,718
Vol ROC: 450.68%
ATR: $0.31
True Range: $0.45
HV 20: 66.4%
HV 30: 71.9%
HV 60: 68.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-11T00:00:00 – 2026-11-09T00:00:00
AI Analysis
Written before INTS’s Nov 5 earnings report, so it doesn’t reflect the results.
Here is my comprehensive stock analysis report for INTS:
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 7)
Key Drivers: Technical sell signals, negative beta, and mixed news sentiment.
Primary Risks: Volatility, potential price drop due to bearish momentum indicators.
Investment Thesis: Avoid INTS until the stock shows signs of reversal or a bullish catalyst emerges. Recent news headlines have been mixed, but technical indicators are bearish, suggesting a potential decline.
Recent News Sentiment Impact: The positive sentiment from recent headlines is somewhat offset by the negative technical signals and risk metrics.
Technical Analysis
Trend Direction: BEARISH (Short-term), NEUTRAL (Medium-term), BEARISH (Long-term)
Support/Resistance Levels:
- Lower band: $3.33
- Middle band: $4.08
- Upper band: $4.83
Momentum Signals:
- RSI interpretation: Neutral (39.75)
- MACD signal: Bearish (-0.31 / Signal: 0.03 / Histogram: -0.34)
- Bollinger Bands position: Neutral
Volume Analysis:
- Volume SMA 20: 29942.88
- On-Balance Volume (OBV): 47015651.75
- Volume Rate of Change: 14.94%
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines outweigh the negative sentiment, but technical signals are bearish.
Sentiment Assessment: NEUTRAL (Positive and neutral sentiments dominate)
Catalyst Identification: No upcoming events or earnings announcements available.
Market Narrative: The mixed news sentiment is not strong enough to overcome the bearish technical signals and risk metrics.
Risk & Volatility Assessment
Beta Interpretation: Stock moves opposite to market (-1.07 beta).
Volatility Regime: High volatility (Stock Volatility: 4.09)
Options Market Signals:
- IV rank: N/A
- Put/call ratios: N/A
- Unusual activity: No unusual options activity detected.
Downside Protection:
- Support levels: $3.33, $4.08
- Risk management considerations: Stop-loss levels at $3.92 and below
Market Context & Positioning
Sector Performance: INTS is underperforming its sector (Technology).
Institutional Activity: No clear institutional activity signals detected.
Correlation Analysis:
- R-squared interpretation: Stock is not strongly correlated with the market (-0.03 correlation).
Relative Valuation: INTS is relatively undervalued within its trading range.
Key Levels & Action Items
Critical Price Levels:
- Support: $3.33, $4.08
- Resistance: $4.83
Breakout/Breakdown Levels:
- Breakdown: $3.92 and below
- Breakout: Above $4.08
Time-Sensitive Catalysts: No time-sensitive catalysts available.
Risk Management:
- Stop-loss levels at $3.92 and below
- Position sizing considerations: 1/2 to 1/3 allocation
Please note that this analysis is based on the provided data, and actual market conditions may differ.
Generated
News
All INTS news →
Enrollment restarts as cash burn rises and partnership talks advance.
INTS Options Activity & IV Rank
Loading options activity...
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 1.1810
Alpha: -106.87%
Correlation: 0.1914
R-Squared: 3.7%
Stock Volatility: 84.9%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
INTS Institutional Ownership (13F)
Filings for 2026-06-30 · 7 already for 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
INTS Insider Trading (Form 4)
Latest: 2026-07-20Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-07-20 | Mark A Goldberg | Director | Grant (A) | +5,500 opt | — | EDGAR | |
| 2026-07-20 | Emer Leahy | Director | Grant (A) | +5,500 opt | — | EDGAR | |
| 2026-07-20 | Lewis H Bender | President and CEO | Grant (A) | +78,000 opt | — | EDGAR | |
| 2026-07-20 | Daniel Donovan | Director | Grant (A) | +5,500 opt | — | EDGAR | |
| 2026-07-20 | Joseph Talamo | Chief Financial Officer | Grant (A) | +34,000 opt | — | EDGAR | |
| 2026-07-20 | John M Wesolowski | Principal Accounting Officer | Grant (A) | +11,000 opt | — | EDGAR | |
| 2026-07-20 | Thomas I H Dubin | Director | Grant (A) | +5,500 opt | — | EDGAR | |
| 2026-07-01 | Joseph Talamo | Chief Financial Officer | Award (A) | +1,093 | $3.48 | $3.8K | EDGAR |
| 2026-07-01 | John M Wesolowski | Principal Accounting Officer | Award (A) | +3,688 | $3.48 | $12.9K | EDGAR |
| 2026-03-30 | Lewis H Bender | President and CEO | Award (A) | +37,749 | $6.11 | $230.6K | EDGAR |
| 2026-01-05 | John M Wesolowski | Principal Accounting Officer | Award (A) | +8,918 | $0.26 | $2.3K | EDGAR |
| 2026-01-05 | Joseph Talamo | Chief Financial Officer | Award (A) | +14,482 | $0.26 | $3.8K | EDGAR |
| 2025-07-02 | Joseph Talamo | Chief Financial Officer | Award (A) | +14,179 | $0.26 | $3.7K | EDGAR |
| 2025-07-02 | John M Wesolowski | Principal Accounting Officer | Award (A) | +69,745 | $0.26 | $18.2K | EDGAR |
| 2025-05-06 | Emer Leahy | Director | Grant (A) | +50,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
INTS Insider Holdings
3 insiders · @ $3.15
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lewis H Bender | President and CEO | 118,549 | $373.4K | $0 | 4 | 2026-07-20 |
| 2 | John M Wesolowski | Principal Accounting Officer | 7,102 | $22.4K | $0 | 10 | 2026-07-20 |
| 3 | Joseph Talamo | Chief Financial Officer | 2,239 | $7.1K | $0 | 7 | 2026-07-20 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
INTS Board & Officers
As of SEC filings through Jul 20, 2026Directors 5
- Daniel Donovan · since Jun 29, 2023
- Emer Leahy · since Jun 29, 2023
- Lewis H Bender · since Jun 29, 2023
- Mark A Goldberg · since Jun 29, 2023
- Thomas I H Dubin · since May 14, 2024
Officers 3
- Lewis H Bender · President and CEO · since Jun 29, 2023
- Joseph Talamo · Chief Financial Officer · since Dec 11, 2023
- John M Wesolowski · Principal Accounting Officer · listed since Jun 2024
Changes in the last 10 years (13)
| Mar 30, 2026 | Lewis H Bender no longer listed as a 10% owner in SEC filings |
| Jun 7, 2024 | John M Wesolowski listed as Principal Accounting Officer (previously Interim CFO) in SEC filings |
| May 21, 2024 | The company announced the departure of James M Ahlers as Executive VP of CF in an SEC filing |
| May 14, 2024 | Thomas I H Dubin became a director |
| Dec 11, 2023 | Joseph Talamo became Chief Financial Officer |
| Jun 29, 2023 | Mark A Goldberg became a director |
| Jun 29, 2023 | Lewis H Bender became a director |
| Jun 29, 2023 | Lewis H Bender became a 10% owner |
| Jun 29, 2023 | Lewis H Bender became President and CEO |
| Jun 29, 2023 | John M Wesolowski became Interim CFO |
| Jun 29, 2023 | James M Ahlers became Executive VP of CF |
| Jun 29, 2023 | Emer Leahy became a director |
| Jun 29, 2023 | Daniel Donovan became a director |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
1 ETF hold INTS
1 shown · $89.54K total exposure
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $89,538 | — | 2026-09-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
INTS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| AMGN Amgen Inc | $249.0B | 27.0 | +8.2% | +42.0% | 32 |
| GILD Gilead Sciences Inc | $207.0B | — | +6.5% | +39.2% | 47 |
| MRNA Moderna, Inc. Common Stock | $101.5B | — | −27.6% | +771.7% | 53 |
| ARGX argenx SE American Depositary Shares | $58.3B | — | — | +14.6% | 58 |
| RVMD Revolution Medicines, Inc. Common Stock | $41.6B | — | — | +153.3% | 60 |
| BIIB Biogen Inc. Common Stock | $36.7B | 108.9 | +2.3% | +43.3% | 100 |
| BNTX BioNTech SE American Depositary Share | $21.7B | — | — | −9.5% | 45 |
| EXEL Exelixis Inc | $17.0B | 21.5 | +9.1% | +64.6% | 47 |
| INTS Intensity Therapeutics, Inc. Common stoc | $10M | — | — | −69.0% | — |
| Peer median | $49.9B | 27.0 | +6.5% | +42.7% | 50 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.